Latest News | Cipla to Price Generic Version of COVID-19 Drug Remdesivir at Less Than Rs 5,000 Per Vial
Get latest articles and stories on Latest News at LatestLY. Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.
New Delhi, Jun 23 (PTI) Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.
"In line with our overall philosophy of driving access and affordability, the drug will be priced at less than Rs 5,000 per vial vial for injection 100 mg -- amongst the lowest pricing for remdesivir globally," Cipla said in an e-mailed response to PTI.
Also Read | Oppo Reno 3 A With Snapdragon 665 Chipset Launched; Check Prices, Features, Variants & Specifications.
On being asked about the launch of the drug, the company said: "We have started commercial manufacturing, and the product will be available in the next 8-10 days."
Hyderbad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose.
Remdesivir is the only United States Food and Drug Administration (USFDA)-approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.
Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need, the company said on Sunday.
In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.
According to the Union health ministry update, the total number of COVID-19 cases in the country stood at 4,40,215 on Tuesday and the death toll was at 14,011.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)